Prothena Corporation technology validated by big Bristol Myers Squibb collaboration
• Bristol Myers is part owner of Prothena
Bristol Myers & Prothena collaboration highlights:
3/20/18 Celgene & Prothena enter master collaboration agreement (Celgene acquired by Bristol Myers - 2019)
• Bristol Myers may elect Prothena Abs against 3 targets
⇒ Tau, TDP-43, & undisclosed
⇒ $100M up-front
⇒ $50M for ~1.2M shares of Prothena
⇒ Prothena eligible for total of $2.2B fees & milestone
6/24/21 Bristol Myers $80M to Prothena for exclusive US rights to PRX005
7/5/23 Bristol Myers $55M to Prothena for exclusive WW rights to PRX005
⇒ Bristol Myers responsible for PRX005 going forward
⇒ Posible milestones now $562.5M
⇒ Reasonable royalty
PRX005 anti-tau Ab
• Binds microtubule binding region (MTBR)
⇒ R1, R2, and R3 repeats
⇒ tau 3R and 4R isoforms
⇒ Ph1 results at AAIC23 (healthy volunteers)
Bristol Myers to give PRX005 updates going forward
Article History:
Originally posted 7/17/23 (RB)
💡 Do you sell your products or services to biopharma companies? 💡
BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.
Comments